Rituximab-associated changes in platelet count in patients with non-Hodgkin lymphoma

References

• Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene 2007; 26: 3603–3613
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Buske C, Dreyling M, Weigert O, Lenz G, Unterhalt M. Current management of follicular lymphomas. Br J Haematol 2007; 136: 191–202
   PubMed Web of Science ®Google Scholar
• Schulz H, Bohlius J F, Trelle S, Skoetz N, Reiser M, Kober T, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007; 99: 706–714
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Thomas D A, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006; 106: 1569–1580
   PubMed Web of Science ®Google Scholar
• Silverman G J. Anti-CD20 therapy and autoimmune disease: therapeutic opportunities and evolving insights. Front Biosci 2007; 12: 2194–2206
   Google Scholar
• Maloney D G, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002; 29(1 Suppl 2)2–9
   PubMed Web of Science ®Google Scholar
• Maloney D G, Grillo-Lopez A J, Bodkin D J, White C A, Liles T M, Royston I, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 3266–3274
   PubMed Web of Science ®Google Scholar
• Anolik J H, Friedberg J W, Zheng B, Barnard J, Owen T, Cushing E, et al. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol 2007; 122: 139–145
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Spedini P, Casari S, Re A, Tucci A, Borlenghi E, et al. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma 2006; 47: 1013–1017
   PubMed Web of Science ®Google Scholar
• Berinstein N L, Grillo-Lopez A J, White C A, Bence-Bruckler I, Maloney D, Czuczman M, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998; 9: 995–1001
   PubMed Web of Science ®Google Scholar
• Maloney D G, Grillo-Lopez A J, White C A, Bodkin D, Schilder R J, Neidhart J A, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188–2195
   PubMed Web of Science ®Google Scholar
• Leo E, Scheuer L, Schmidt-Wolf I G, Kerowgan M, Schmitt C, Leo A, et al. Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma. Eur J Haematol 2004; 73: 251–257
   PubMed Web of Science ®Google Scholar
• Larrar S, Guitton C, Willems M, Bader-Meunier B. Severe hematological side effects following Rituximab therapy in children. Haematologica 2006; 91(8 Suppl)ECR36
   PubMedGoogle Scholar
• Otrock Z K, Mahfouz R A, Oghlakian G O, Salem Z M, Bazarbachi A. Rituximab-induced acute thrombocytopenia: a report of two cases. Haematologica 2005; 90(Suppl)ECR23
   PubMedGoogle Scholar
• Pamuk G E, Donmez S, Turgut B, Demir M, Vural O. Rituximab-induced acute thrombocytopenia in a patient with prolymphocytic leukemia. Am J Hematol 2005; 78: 81
   PubMed Web of Science ®Google Scholar
• Shah C, Grethlein S J. Case report of rituximab-induced thrombocytopenia. Am J Hematol 2004; 75: 263
   PubMed Web of Science ®Google Scholar
• Rosado M, Chao H, Rose M. Severe acute thrombocytopenia following rituximab therapy. Leuk Lymphoma 2007; 48: 2239–2240
   PubMed Web of Science ®Google Scholar
• Byrd J C, Murphy T, Howard R S, Lucas M S, Goodrich A, Park K, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001; 19: 2153–2164
   PubMed Web of Science ®Google Scholar
• Hauser S L, Waubant E, Arnold D L, Vollmer T, Antel J, Fox R J, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676–688
   PubMed Web of Science ®Google Scholar
• Aster R H, Bougie D W. Drug-induced immune thrombocytopenia. N Engl J Med 2007; 357: 580–587
   PubMed Web of Science ®Google Scholar
• Haider I, Cahill M. Fatal thrombocytopaenia temporally related to the administration of alemtuzumab (MabCampath) for refractory CLL despite early discontinuation of therapy. Hematology 2004; 9(5-6)409–411
   PubMedGoogle Scholar
• Cathomas R, Goldhirsch A, von Moos R. Drug-induced immune thrombocytopenia. N Engl J Med 2007; 357: 1870–1871, author reply 1871
   PubMed Web of Science ®Google Scholar
• Davis T A, White C A, Grillo-Lopez A J, Velásquez W S, Link B, Maloney D G, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999; 17: 1851–1857
   PubMed Web of Science ®Google Scholar
• Provan D, Butler T, Evangelista M L, Amadori S, Newland A C, Stasi R. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica 2007; 92: 1695–1698
   PubMed Web of Science ®Google Scholar
• Ammatuna E, Marino C, Mitra M E, Calvaruso G, Iannitto E. Successful treatment of steroid resistant autoimmune thrombocytopenia associated with chronic lymphocytic leukemia with alemtuzumab. Eur J Haematol 2004; 73: 225–226
   PubMed Web of Science ®Google Scholar
• Arnold D M, Kelton J G. Current options for the treatment of idiopathic thrombocytopenic purpura. Semin Hematol 2007; 44(4 Suppl 5)S12–S23
   PubMed Web of Science ®Google Scholar
• Chung J, Rader C, Popkov M, Hur Y M, Kim H K, Lee Y J, et al. Integrin alphaIIbbeta3-specific synthetic human monoclonal antibodies and HCDR3 peptides that potently inhibit platelet aggregation. FASEB J 2004; 18: 361–363
   PubMed Web of Science ®Google Scholar